logo
Serta Simmons Bedding Launches Serta® Perfect Day® Mattress in a Box Collection

Serta Simmons Bedding Launches Serta® Perfect Day® Mattress in a Box Collection

DORAVILLE, Ga.--(BUSINESS WIRE)--Jul 16, 2025--
Serta Simmons Bedding (SSB), a leading global sleep company, today announced the launch of the new Serta ® Perfect Day ® Mattress in a Box (MIB) collection – designed to deliver refreshing sleep, zoned support, and Serta-quality comfort at compelling price points and ultimate convenience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716965976/en/
The new Serta® Perfect Day® Mattress in a Box (MIB) collection, designed to deliver refreshing sleep, zoned support, and Serta-quality comfort at compelling price points and ultimate convenience
The new Perfect Day collection includes a range of wrapped coil mattresses engineered for instant recovery and support the moment they're unboxed: from Box-to-Bed in Seconds™ making setup simple for consumers for immediate use.
With breathable materials, layers of cushioning foam, and signature 3-Zoned Body Support for enhanced lower-back support, the collection is designed to offer consumers a perfect night's sleep for an unbeatable value.
'Perfect Day represents the sweet spot between performance, value and convenience,' said Mitch Willingham, Senior Vice President, Brand Marketing. 'Whether it's a guest room upgrade or a first mattress out of college, consumers want reliable comfort from a brand they trust – and Perfect Day delivers exactly that in a box.'
About the Serta ® Perfect Day ® Mattress in a Box Collection
The Perfect Day collection includes four comfort tiers – from a 7" firm entry-level model at suggested Queen pricing of $199 (level 1) to a 16" plush pillow top at suggested Queen pricing of $1,099 (level 4) – each designed to meet different sleep preferences while maintaining a consistent standard of quality, breathability, and support.
Key product benefits include:
Made in the USA with global components, and available in sizes from twin through California king, the line spans nine models, including firm, medium, plush and pillow top comfort options, with suggested Queen pricing starting at $199 and going up to $1,099.
Driving Growth in the Value Segment
'With Perfect Day, we're extending the Serta promise to a new generation of value-conscious and convenience-focused shoppers,' said Willingham. 'We are meeting consumers where they are – whether that's online or in-store – and driving performance for our retail partners.'
Perfect Day models are compressed, boxed, and ready to ship or carry home, and they're also available as flat mattresses for retailer in-store display.
For more information on all Serta products, visit https://www.serta.com
About Serta Simmons Bedding
Serta Simmons Bedding (SSB) is one of the leading global sleep companies. With a 150-year heritage in delivering industry-leading sleep solutions and a mission to help people sleep better so they can live healthier lives, the company is headquartered in Doraville, GA, and owns top brands such as Serta ®, which has five other independent licensees, Beautyrest ®, Tuft & Needle ® and Beauty Sleep ®. For more information about SSB and its brands, visit https://sertasimmons.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250716965976/en/
CONTACT: Media Contact:
Jamie Wallis
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: HOME GOODS RETAIL OTHER RETAIL
SOURCE: Serta Simmons Bedding
Copyright Business Wire 2025.
PUB: 07/16/2025 07:51 AM/DISC: 07/16/2025 07:51 AM
http://www.businesswire.com/news/home/20250716965976/en
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025
STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

Business Wire

time2 hours ago

  • Business Wire

STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Time: 4:30 p.m. ET Location: The live webcast, including an option to pre-register, can be accessed at the preceding link or the 'Investors' section of the STAAR website at A webcast replay will be available at the same link for at least 90 days. About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at

Daily Journal Corporation Provides Additional Public Access to its Recent Form 8-K
Daily Journal Corporation Provides Additional Public Access to its Recent Form 8-K

Business Upturn

time4 hours ago

  • Business Upturn

Daily Journal Corporation Provides Additional Public Access to its Recent Form 8-K

Contact: Jessica Marshall (778)716-6706 LOS ANGELES, July 31, 2025 (GLOBE NEWSWIRE) — Daily Journal Corporation is issuing this press release to provide additional public access to the Form 8-K it filed earlier this week with the Securities and Exchange Commission in response to the incredible interest in our software accounting expressed by Buxton Helmsley USA, Inc. and its Chairman and CEO, Alexander E. Parker. Below is the text of our Form 8-K. You can also visit our website at for copies of Mr. Parker's correspondence. Item 8.01 Other Events. Two weeks ago, we received a letter from Alexander E. Parker at a firm called Buxton Helmsley USA, Inc. The letter said Daily Journal Corporation (the 'Company') should be capitalizing software development costs instead of expensing them under GAAP, and that doing so would 'unlock $160+ million in incremental equity value' for shareholders. Mr. Parker then asked for a consulting engagement that would pay him $24 million worth of Company equity if the stock price increased by that amount for any reason (i.e., $.15 of every dollar), and he asked for two seats on the Company's Board of Directors. His initial July 14 letter is attached as Exhibit 99.1, and his follow-up letter dated July 18 (demanding an emergency Board meeting) is attached as Exhibit 99.2. According to the SEC's website, neither Mr. Parker nor Buxton Helmsley is registered as an investment adviser with the SEC. The Buxton Helmsley website says that Mr. Parker is licensed by FINRA, but according to the FINRA website, he is not registered as a broker or investment adviser. His LinkedIn page says that Mr. Parker attended Mercy University from 2014 to 2016. Mr. Parker seems to fancy himself a whistleblower, but the Company has been disclosing its practice of expensing software development costs and the reasons for that in its public filings for more than a decade. Nothing is hidden. The Company is well aware of the accounting rules under ASC 985-20, Costs of Software to be Sold, Leased, or Otherwise Marketed, and those rules require a continuous facts-and-circumstances analysis. The Company believes the accounting for its eSeries® product line development efforts is, and has been, correct. Furthermore, the Company's approach has been reviewed as part of the annual audit without issue by three different national accounting firms since those development efforts began. Mr. Parker is right that if the Company capitalized those costs, it would boost near-term earnings and asset values by reducing the Company's expenses and shifting them to the balance sheet. Anyone who knew our longtime Chairman, Charles T. Munger, knows what his thoughts would have been on the idea of 'creating value' through accounting. Nonetheless, the Board and its Audit Committee decided to take this opportunity to engage an independent accounting consultant to make sure the Company is accounting for software development costs correctly. And that's when Mr. Parker's game became clear. On July 23, one day after being informed of the decision to engage an independent accounting firm rather than Buxton Helmsley, Mr. Parker fired back a letter saying that only Buxton Helmsley was qualified to 'restore trust' while at the same time notifying us that he was reporting the Company to the Enforcement Division of the SEC. That letter is attached as Exhibit 99.3. You should read it. We suspect Mr. Parker will learn with age and experience that few people want to work with someone who presents himself this way. Even fewer want to work with someone who reports them to the government when he doesn't get what he wants! Also, we've already reached out to the SEC staff and have offered to discuss with them the Company's software development accounting and/or Mr. Parker, should they so desire. Finally, we are attaching an email chain with Mr. Parker as Exhibit 99.4, and Mr. Parker's fourth letter, this one dated July 25, as Exhibit 99.5. This most recent letter is addressed to Company stockholders and calls for the immediate resignation of both the Company's CEO and its CFO. Remember, all that's happened here is that the Company's Audit Committee decided to engage an independent accounting consultant instead of him! After considering Mr. Parker's analysis, his demand for equity compensation and his threats should the Company challenge him (see page 5 of the July 23 letter in particular), we suspect Company shareholders will agree that the Audit Committee made a prescient and wise decision in not 'partnering' with Mr. Parker. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Letter from Buxton Helmsley USA, Inc., dated July 14, 2025. 99.2 Letter from Buxton Helmsley USA, Inc., dated July 18, 2025. 99.3 Letter from Buxton Helmsley USA, Inc., dated July 23, 2025. 99.4 Various correspondence Alexander E. Parker between July 14 and July 23, 2025. 99.5 Letter from Buxton Helmsley USA, Inc., dated July 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) # Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Yahoo

time8 hours ago

  • Yahoo

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis. In September 2021, Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as MONJUVI® in the United States and MINJUVI® outside of the U.S.), as well as PEMAZYRE® (pemigatinib), in Latin America. In February 2024, Knight announced the launch of MINJUVI® in Brazil in combination with lenalidomide followed by MINJUVI® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). 'This regulatory submission for a new indication for tafasitamab in relapsed or refractory FL highlights our steadfast commitment to bringing innovation and enhancing quality of life and care,' said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics. 'If approved, the combination of tafasitamab, rituximab and lenalidomide will be an important new therapeutic option for eligible adult patients with previously treated FL in Brazil. We look forward to continuing to work towards regulatory submissions in additional countries in Latin America over the next months.' About Follicular Lymphoma (FL) and inMIND Study FL is the most common indolent, or slow growing, form of non-Hodgkin lymphoma (NHL).1 In Brazil, according to the 2023 data from the National Cancer Institute (INCA) Registries, the expected incidence/year of NHL (inclusive of all subtypes) was 5.57 per 100, 000 in the general population, 6.42 per 100,000 in the male population, and 5.62 per 100,000 in the female population. It is expected that follicular lymphoma constitutes 20% to 25% of adult NHL cases.2,3,4 There are limited treatment options for relapsed or refractory FL.5 The submission is based on the results from the pivotal Phase 3 inMIND trial, a double-blind, placebo-controlled trial randomizing 548 patients with relapsed or refractory FL to receive tafasitamab or placebo with lenalidomide and rituximab. Key results from the trial demonstrated that tafasitamab plus lenalidomide and rituximab significantly improved progression-free survival (PFS) in patients with relapsed or refractory FL compared to a placebo. The median PFS was 22.4 months in the treatment arm versus 13.9 months in the placebo arm, representing a 57% reduction in the risk of disease progression, relapse, or death. Secondary endpoints also showed improvements, with higher response rates and longer durations of response observed in the treatment arm.6 About MINJUVI® (tafasitamab)MINJUVI® (tafasitamab) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. In the U.S., MONJUVI® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). MONJUVI® is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials. Additionally, MONJUVI® received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). In Europe, MINJUVI® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. XmAb® is a registered trademark of Xencor, Inc. MONJUVI, MINJUVI, the MINJUVI and MONJUVI logos and the 'triangle' design are registered trademarks of Incyte. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. References: Kaseb H, et al. Follicular Lymphoma. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Kanters S, et al. BMC Cancer. 2023;23:74. Smith SM, Salles G. Haematologica. 2022;107:4-6. Swerdlow SH, Campo E, Pileri SA, et al. Blood. 2016;127:2375-2390. Decision Resources Group. Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Landscape & Forecast. 2020. Sehn L H., et al. ASH Annual Meeting 2024; Late Breaking Abstract Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND). Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store